Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: Overcoming lies, damn lies, and statistics

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1466-1470

  Ambrose, Paul G ^a,b,c   Hammel, Jeffrey P ^a   Bhavnani, Sujata M ^a,c   Rubino, Christopher M ^a,c   Ellis Grosse, Evelyn J ^d   Drusano, George L ^e  

^a INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY AT BUFFALO   (United States)

^d E2g Biopharmaceutical Consulting   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TIGECYCLINE;

AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CONFIDENCE INTERVAL; FREQUENTIST ANALYSIS; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PROBABILITY; STATISTICAL ANALYSIS;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BAYES THEOREM; BIOMARKERS, PHARMACOLOGICAL; CROSS INFECTION; GRAM-POSITIVE BACTERIA; HUMANS; LOGISTIC MODELS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME;

EID: 84857166213     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01743-10     Document Type: Article

References (21)

1. Ambrose PG, Bhavnani SM, Ellis-Grosse EJ, Drusano GL. 2010. Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator associated bacterial pneumonia studies: look before you leap! Clin. Infect. Dis. 51(Suppl 1):S103-S110.
2. Ambrose PG, et al. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86. (Pubitemid 44968990)
3. Bhavnani SM, et al. 2012. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob. Agents Chemother. 56:1065-1072.
4. Bhavnani SM, et al. 2010. Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections. Antimicrob. Agents Chemother. 54:1207-1212.
5. Reference deleted.
6. Davison AC, Hinkley DV. 1997. Bootstrap methods and their application. Cambridge University Press, Cambridge, United Kingdom.
7. DiCiccio TJ, Efron B. 1996. Bootstrap confidence intervals (with discussion). Stat. Sci. 11:189-228.
8. Freire AT, et al. 2010. Comparison of tigecycline with imipenem/ cilastatin for the treatment of hospital-acquired pneumonia. Diagn. Microbiol. Infect. Dis. 68:140-151.
9. Greer ND. 2006. Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc. (Bayl. Univ. Med. Cent.) 19:155-161.
10. Meagher AK, et al. 2007. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob. Agents Chemother. 51:1939-1945. (Pubitemid 46903077)
11. Passarell JA, et al. 2008. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob. Agents Chemother. 52:204-210.
12. R Development Core Team. 2008. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
13. Snodgrass WR, Anderson T. 1937. Sulphanilamide in the treatment of erysipelas. A controlled series of 270 cases. Br. Med. J. 2:1156-1159.
14. Snodgrass WR, Anderson T. 1937. Prontosil in the treatment of erysipelas. A controlled series of 312 cases. Br. Med. J. 2:101-104.
15. US Department of Health and Human Services and US Food and Drug Administration. 2010. Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment. US Department of Health and Human Services and US Food and Drug Administration, Washington, DC.
16. US Department of Health and Human Services and US Food and Drug Administration. 2010. Guidance for industry: hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia: developing drugs for treatment. US Department of Health and Human Services and US Food and Drug Administration, Washington, DC.
17. US Department of Health and Human Services and US Food and Drug Administration. 2010. Guidance for industry: non-inferiority clinical trials. US Department of Health and Human Services and US Food and Drug Administration, Washington, DC.
18. US Food and Drug Administration. 2007. Clinical trial design for community-acquired pneumonia: public workshop. January 17-18, 2008. Fed. Regist. 72:73028-73029. http://www.fda.gov/drugs/newsevents/ucm180241.htm.
19. US Food and Drug Administration. 2009. Docket no. FDA-2009-N-0664. Clinical trial design for hospital-acquired pneumonia and ventilator-associated pneumonia. Public workshop. March 31-April 1, 2009. Fed. Regist. 74:35. http://www.fda.gov/downloads/drugs/newsevents/ucm169943.pdf.
20. US Food and Drug Administration. 2011. Code of federal regulations, title 21, parts 50, 54, 56, 312, and 314. US Food and Drug Administration, Washington, DC. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/ cfrsearch.cfm.
21. van Ogtrop ML, et al. 2000. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Grampositive and Gram-negative bacteria. Antimicrob. Agents Chemother. 44: 943-949.